Cannabidiol and substance use disorder: Dream or reality

Karimi‐Haghighi, Saeideh; Razavi, Yasaman; Iezzi, Daniela; Scheyer, Andrew F.; Manzoni, Olivier J.; Haghparast, Abbas

doi:10.1016/j.neuropharm.2022.108948

Cited by 26 publications

(20 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31,32,46 Additionally, as there is currently no evidence on the impact of CBD on methamphetamine use and current treatments are limited in efficacy, this is also a worthwhile future direction. High Karimi-Haghighi et al 30 2 2 0 2 2 2 10 Moderate Kudrich et al 31 2 2 2 2 2 2 12 High Legare et al 32 2 1 1 2 2 2 10 Moderate Morel et al 38 2 2 2 2 2 2 12 High Navarrete et al 9 2 2 2 2 2 2 12 High Pauli et al 39 2 2 0 2 2 2 10 Moderate Sloan et al 43 2 2 0 2 2 2 10 Moderate Spanagel 44 2 1 0 2 2 2 9 Moderate Wiese and Wilson-Poe 46 1 0 0 2 2 2 7 Low…”

Section: Research Gaps and Future Directionsmentioning

confidence: 99%

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Lo,

MacCallum,

Nanson

et al. 2023

Can J Psychiatry

View full text Add to dashboard Cite

Objective The drug poisoning crisis throughout North America necessitates novel harm reduction approaches. Emerging evidence suggests that cannabidiol (CBD) may have some utility as a harm reduction modality for those with problematic substance use. This rapid review aimed to synthesize available evidence on CBD as a potential harm reduction tool for people who use drugs while providing clinical and research insights. Method A systematic search in EMBASE, MEDLINE, CENTRAL, and CINAHL was completed in July 2022. For inclusion, studies had to meet the following criteria: (1) drawn from an adult population of people who use drugs; (2) investigates CBD as an intervention for problematic substance use or harm reduction–related outcomes; (3) be published after the year 2000 and in English; and (4) be primary research or a review article. A narrative synthesis was used to group outcomes relevant to harm reduction and provide clinical and research insights. Results We screened 3,134 records, of which 27 studies (5 randomized trials) were included. The evidence remains limited, but available studies support the potential utility of CBD to reduce drug-induced craving and anxiety in opioid use disorder. There were low-quality studies suggesting that CBD may improve mood and general well-being of people who use drugs. Evidence suggests that CBD monotherapy may not be an adequate harm reduction strategy for problematic substance use but rather an adjunct to the standard of care. Conclusion Low-quality evidence suggests that CBD may reduce drug cravings and other addiction-related symptoms and that CBD may have utility as an adjunct harm reduction strategy for people who use drugs. However, there is a significant need for more research that accurately reflects CBD dosing and administration regimens used in a real-world context.

show abstract

Section: Research Gaps and Future Directionsmentioning

confidence: 99%

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Lo,

MacCallum,

Nanson

et al. 2023

Can J Psychiatry

View full text Add to dashboard Cite

show abstract

“…However, the underlying mechanisms were not identified since CBD has a multi-target pharmacological profile. CBD interacts directly and indirectly with different neurotransmission systems (i.e., dopaminergic, serotoninergic, endocannabinoid and, opioid systems), signaling pathways (such as BDNF, mTOR and Wnt pathways), and inflammatory response regulators (PPARɤ, IL-1β, IL-6, TNF-α), among others targets (Calpe-López et al, 2019; Karimi-Haghighi et al, 2020; Karimi-Haghighi et al, 2022; Echeverry et al, 2023). Therefore, the present study was designed to identify and investigate the main mechanisms underlying the CBD’s ability to prevent the locomotor sensitization induced by the combined administration of cocaine and caffeine using a genome-wide approximation.…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol prevents the locomotor sensitization induced by cocaine and caffeine and upregulates genes of extracellular matrix and anti-inflammatory pathways in the nucleus accumbens: a transcriptome-wide analysis

Prieto,

Fort,

Eastman

et al. 2023

Preprint

View full text Add to dashboard Cite

Cannabidiol (CBD), a non-psychotomimetic phytocannabinoid found in theCannabisplant, has emerged as a potential therapeutic agent for psychostimulant use disorders. In recent work, we demonstrated that CBD is able to attenuate the expression of locomotor sensitization and the enhanced metabolic activity in the nucleus accumbens (NAc) generated by the combination of cocaine and caffeine. CDB interacts directly or indirectly with several molecular targets, so the underlying mechanisms of its beneficial effects are hard to determine. Here we used high-throughput RNA-sequencing in mice’s NAc after a sensitization protocol with combined cocaine plus caffeine and a CBD pre-treatment, to identify the major pathways and genes involved in CBD attenuating behavioral effects. Results indicated that CBD pretreatment consistently reduced both the acquisition and expression of cocaine and caffeine locomotor sensitization. The transcriptome analysis revealed that CBD pre-treatment enriched genes and functional association between proteins mainly related to extracellular matrix (ECM) organization and cell interactions in the NAc. Moreover, the neuroinflammation and BDNF signaling pathways were also influenced by CBD. Some specially enriched genes such as Tnc were identified as interesting specific candidates for follow-up studies. These findings provide valuable and novel insights into molecular mechanisms of CBD putatively associated with a protective effect on psychostimulant actions. A better understanding of the therapeutic targets of CBD can open new avenues for psychostimulant use disorder treatment strategies.

show abstract

“…Although not psychotropic, CBD is a psychoactive molecule that binds CB1R, CB2R, TRPV1R, PPAR-γ as well as numerous non-cannabinoid receptors, including several G proteins (GPR55, GPR3, GPR6, and GPR12), serotonin 5-HT receptor, mu and delta opioid receptors, type 2 dopamine receptor (D2R), γ-Aminobutyric acid (GABA) type A receptor and Glycine α3 receptors [3]. Its clinical interest is due to its potential benefits as a natural antipsychotic, anti-nociceptive, anticonvulsant, antiemetic, anxiolytic, anti-inflammatory, antioxidant, and neuroprotective agent [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner

et al. 2022

Self Cite

View full text Add to dashboard Cite

Cannabidiol (CBD), one of the main components of cannabis, is generally considered safe. CBD crosses the placenta and its use during pregnancy is steadily increasing, the impact of gestational CBD’s effects on prenatal life and neurodevelopment are poorly understood. Here, we combined behavioral approaches and deep learning analysis to assess the sex-dependent neonatal behavior of CBD exposed progeny. Gestating C57BL6/J dams were exposed daily with vehicle or CBD (3 mg/Kg, s.c.), from gestational day 5 to 18. Body weight, pup ultrasound vocalizations (USVs, PND 10) and homing behavior (PND 13) were quantified in the progeny. Thus, male (but not female) pups from CBD-treated dams gained more weight than sham. There were sex-dependent differences in the coarse characteristics of ultrasonic vocalizations. Prenatally-CBD exposed male pups emitted shorter calls, whereas CBD females made more high frequency calls when compared with their control counterparts. There were significant qualitative changes in the syllabic USV repertoire reflected in call typologies and communication patterns. Finally, the homing behavior test showed that CBD-exposed females presented a greater vulnerability to gestational CBD than males. Only CBD-exposed female pups showed reduced motor and discriminatory abilities. Together the results suggest a sexual divergence in the consequences of in utero CBD exposure on neonates at early developmental ages, which may be predictive of adult psychopathology. Given the extent of cannabis and CBD use worldwide, these findings challenge the idea that CBD is a universally safe compound and reveal the need for additional studies on the effect of perinatal CBD exposure.

show abstract

Cannabidiol and substance use disorder: Dream or reality

Cited by 26 publications

References 188 publications

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Cannabidiol as a Harm Reduction Strategy for People Who Use Drugs: A Rapid Review

Cannabidiol prevents the locomotor sensitization induced by cocaine and caffeine and upregulates genes of extracellular matrix and anti-inflammatory pathways in the nucleus accumbens: a transcriptome-wide analysis

In utero exposure to cannabidiol disrupts select early-life behaviors in a sex-specific manner

Contact Info

Product

Resources

About